Placebo-controlled pilot study of ramelteon for adiposity and lipids in patients with schizophrenia

Journal of Clinical Psychopharmacology

Volumn 31, Issue 5, 2011, Pages 653-658

  Borba, Christina P C ^a,b   Fan, Xiaoduo ^a,b   Copeland, Paul M ^b,c   Paiva, Alexander ^a   Freudenreich, Oliver ^a,b   Henderson, David C ^a,b  

^a Freedom Trail Clinic   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

glucose metabolism; insulin resistance; obesity; Ramelteon; schizophrenia

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LIPID; PLACEBO; RAMELTEON;

ADULT; AGED; AKATHISIA; ANTHROPOMETRY; ANXIETY; ARTHRALGIA; ARTICLE; BODY FAT; BODY HEIGHT; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; DAYTIME FATIGUE; DEMOGRAPHY; DOUBLE BLIND PROCEDURE; DROWSINESS; DUAL ENERGY X RAY ABSORPTIOMETRY; FATIGUE; FEMALE; GLUCOSE METABOLISM; HEARTBURN; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; METABOLIC DISORDER; MYALGIA; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SIDE EFFECT; SLEEP QUALITY; URINARY FREQUENCY; WAIST CIRCUMFERENCE;

ADIPOSITY; ADOLESCENT; ADULT; AGED; ANTHROPOMETRY; ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDENES; LIPIDS; MALE; MIDDLE AGED; OBESITY; PILOT PROJECTS; SCHIZOPHRENIA; YOUNG ADULT;

EID: 80052454453     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31822bb573     Document Type: Article

References (31)

1. Ananth J, Venkatesh R, Burgoyne K, et al. Atypical antipsychotic induced weight gain: pathophysiology and management. Ann Clin Psychiatry. 2004;16:75-85. (Pubitemid 39070973)
2. Henderson DC. Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence? CNS Drugs. 2002;16:77-89. (Pubitemid 34155205)
3. Henderson DC. Schizophrenia and comorbid metabolic disorders. J Clin Psychiatry. 2005;66(suppl 6):11-20. (Pubitemid 41243257)
4. Henderson DC, Cagliero E, Copeland PM, et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry. 2005;62:19-28. (Pubitemid 40096067)
5. Carr DB, Utzschneider KM, Hull RL, et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes. 2004;53:2087-2094. (Pubitemid 38970759)
6. Hayashi T, Boyko EJ, Leonetti DL, et al. Visceral adiposity and the risk of impaired glucose tolerance: a prospective study among Japanese Americans. Diabetes Care. 2003;26:650-655. (Pubitemid 36929322)
7. Jensen MD, Haymond MW, Rizza RA, et al. Influence of body fat distribution on free fatty acid metabolism in obesity. J Clin Invest. 1989;83:1168-1173. (Pubitemid 19113028)
8. Monteleone P, Natale M, La Rocca A, et al. Decreased nocturnal secretion of melatonin in drug-free schizophrenics: no change after subchronic treatment with antipsychotics. Neuropsychobiology. 1997;36:159-163. (Pubitemid 27472513)
9. Raskind MA, Burke BL, Crites NJ, et al. Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats. Neuropsychopharmacology. 2007;32: 284-288. (Pubitemid 46106935)
10. Bersani G, Mameli M, Garavini A, et al. Reduction of night/day difference in melatonin blood levels as a possible disease-related index in schizophrenia. Neuro Endocrinol Lett. 2003;24:181-184. (Pubitemid 37074810)
11. Shamir E, Laudon M, Barak Y, et al. Melatonin improves sleep quality of patients with chronic schizophrenia. J Clin Psychiatry. 2000;61: 373-377. (Pubitemid 30345940)
12. Shamir E, Rotenberg VS, Laudon M, et al. First-night effect of melatonin treatment in patients with chronic schizophrenia. J Clin Psychopharmacol. 2000;20:691-694.
13. Johnson MW, Suess PE, Griffiths RR. Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects. Arch Gen Psychiatry. 2006;63:1149-1157. (Pubitemid 44500632)
14. Spitzer RL, Williams JB, Gibbon M, et al. The Structured Clinical Interview for DSM-III-R (SCID). I: history, rationale, and description. Arch Gen Psychiatry. 1992;49:624-629.
15. Borja NL, Daniel KL. Ramelteon for the treatment of insomnia. Clin Ther. 2006;28:1540-1555. (Pubitemid 44841983)
16. Durnin JV, Womersley J. Body fat assessed from total body density and its estimation from skinfold thickness: measurements on 481 men and women aged from 16 to 72 years. Br J Nutr. 1974;32:77-97.
17. Henderson DC, Cagliero E, Copeland PM, et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotics agents. A frequently sampled intravenous glucose tolerance test and Minimal Model analysis. Arch Gen Psych. 2005;62:19-28. (Pubitemid 40096067)
18. Kelly TL, Berger N, Richardson TL. DXA body composition: theory and practice. Appl Radiat Isot. 1998;49:511-513. (Pubitemid 28150034)
19. Visser M, Fuerst T, Lang T, et al. Validity of fan-beam dual-energy X-ray absorptiometry for measuring fat-free mass and leg muscle mass. Health, Aging, and Body Composition StudyVDual-Energy X-ray Absorptiometry and Body Composition Working Group. J Appl Physiol. 1999;87:1513-1520.
20. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
21. Perez-Martin A, Raynaud E, Hentgen C, et al. Simplified measurement of insulin sensitivity with the minimal model procedure in type 2 diabetic patients without measurement of insulinemia. Horm Metab Res. 2002;34:102-106. (Pubitemid 34208317)
22. Hermans MP, Levy JC, Morris RJ, et al. Comparison of insulin sensitivity tests across a range of glucose tolerance from normal to diabetes. Diabetologia. 1999;42:678-687. (Pubitemid 29265585)
23. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANNS) for schizophrenia. Schizophr Bull. 1987;13:261-276. (Pubitemid 18039085)
24. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
25. Heinrichs DW, Hanlon TE, Carpenter WT Jr. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull. 1984;10:388-398.
26. Hoddes E, Zarcone V, Smythe H, et al. Quantification of sleepiness: a new approach. Psychophysiology. 1973;10:431-436.
27. Hays RD, Martin SA, Sesti AM, et al. Psychometric properties of the Medical Outcomes Study Sleep measure. Sleep Med. 2005;6:41-44.
28. Levine J, Schooler NR. SAFTEE: a technique for the systematic assessment of side effects in clinical trials. Psychopharmacol Bull. 1986;22:343-381. (Pubitemid 16043808)
29. Evans DR, Parikh VV, Khan MM, et al. Red blood cell membrane essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatment. Prostaglandins Leukot Essent Fatty Acids. 2003;69:393-399. (Pubitemid 37464048)
30. Sateia MJ, Kirby-Long P, Taylor JL. Efficacy and clinical safety of ramelteon: an evidence-based review. Sleep Med Rev. 2008;12:319-332. (Pubitemid 351899319)
31. Haslemo T, Eikeseth PH, Tanum L, et al. The effect of variable cigarette consumption on the interaction with clozapine and olanzapine. Eur J Clin Pharmacol. 2006;62:1049-1053. (Pubitemid 44786497)